Regeneron Accused of Hiding ‘Hundreds of Millions’ in Eylea Credit Card Fees from Medicare
Albany, New York – A complaint has been filed against pharmaceutical company Regeneron alleging that it concealed a significant amount of credit card processing fees related to its drug Eylea from Medicare. The Department of Justice (DOJ) claims that Regeneron purposely failed to report these fees, amounting to ‘hundreds of millions’ of dollars, to Medicare. Regeneron’s Eylea is a widely used medication for treating certain eye conditions, including wet age-related macular degeneration. The complaint against …